Roche's Faricimab Receives NMPA Approval for New Indication in China to Treat Macular Edema Following Central Retinal Vein Occlusion

Intelligent Finance APP learned on October 14 that the official website of China's National Medical Products Administration (NMPA) announced the approval of Roche's (RHHBY.US) Faricimab Injection for a new indication. According to Roche’s previous press release, this is the fourth indication for Faricimab approved in China, used for treating macular edema secondary to central retinal vein occlusion (CRVO).

It is reported that Retinal Vein Occlusion (RVO) is a retinal vascular disease caused by partial or complete obstruction of the retinal vein due to various reasons, leading to impaired blood reflux in the retinal venous system, and subsequently manifesting as retinal vein dilation and retinal hemorrhage. Based on the site of vascular occlusion, it can be divided into two types: BRVO and CRVO.